49
© 2016 by the authors. This work is licensed under a Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International License.
25. Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann
Intern Med. 2002;136(3):254-9.
26. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering.
Lancet. 2002;359(9306):614-8.
27. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early
renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society
(ANZICS) Clinical Trials Group. Lancet. 2000;356(9248):2139-43.
28. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus
conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a
prospective, randomised, double-blind trial. Lancet. 2001;357(9256):577-81.
29. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in
general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357(9250):89-95.
30. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and
short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet. 2000;356(9240):1480-5.
31. Fu R, Vandermeer BW, Shamliyan TA, O'Neil ME, Yazdi F, Fox SH, et al. AHRQ Methods for Effective
Health Care: Handling Continuous Outcomes in Quantitative Synthesis. Methods Guide for Effectiveness and
Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008.
32. Schulz KF. Subverting randomization in controlled trials. JAMA. 1995;274(18):1456-8.
33. Wright IS, Marple CD, Beck DF. Report of the Committee for the Evaluation of Anticoagulants in the
Treatment of Coronary Thrombosis with Myocardial Infarction; a progress report on the statistical analysis of
the first 800 cases studied by this committee. Am Heart J. 1948;36(6):801-15.
34. Trowman R, Dumville JC, Torgerson DJ, Cranny G. The impact of trial baseline imbalances should be
considered in systematic reviews: a methodological case study. J Clin Epidemiol. 2007;60(12):1229-33.
35. Badawy MSH, Hassanin IMA. The value of magnesium sulfate nebulization in treatment of acute
bronchial asthma during pregnancy. Egyptian Journal of Chest Diseases and Tuberculosis. 2014;63(2):285-9.
36. Altman DG, Bland JM. How to randomize. BMJ. 1999;319:703-4.
37. Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research.
Clin Trials. 2012;9(1):48-55.
38. Shrier I, Steele RJ, Verhagen E, Herbert R, Riddell CA, Kaufman JS. Beyond intention to treat: what is
the right question? Clin Trials. 2014;11(1):28-37.
39. Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hrobjartsson A, et al. Methods of blinding in
reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med.
2006;3(10):e425.
40. Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a
random sample of randomised, placebo controlled trials. BMJ. 2004;328(7437):432.
41. Rees JR, Wade TJ, Levy DA, Colford JM, Jr., Hilton JF. Changes in beliefs identify unblinding in
randomized controlled trials: a method to meet CONSORT guidelines. Contemp Clin Trials. 2005;26(1):25-37.
42. Hrobjartsson A, Forfang E, Haahr MT, Als-Nielsen B, Brorson S. Blinded trials taken to the test: an
analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol. 2007;36(3):654-
63.
43. Sackett DL. Commentary: Measuring the success of blinding in RCTs: don't, must, can't or needn't? Int
J Epidemiol. 2007;36(3):664-5.
44. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations
and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001;285(15):2000-3.
45. Boutron I, Estellat C, Ravaud P. A review of blinding in randomized controlled trials found results
inconsistent and questionable. J Clin Epidemiol. 2005;58(12):1220-6.
46. Haahr MT, Hrobjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a
survey of authors. Clin Trials. 2006;3(4):360-5.
47. Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH. In the dark: the reporting of
blinding status in randomized controlled trials. J Clin Epidemiol. 2002;55(8):787-90.
48. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel
group randomised trials. BMJ. 2010;340:c332.
49. Hrobjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient
blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies.
Int J Epidemiol. 2014;43(4):1272-83.